Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
12-May-2025 | 616.1 | 627.45 | 612.4 | 625.6 | 28,146 | 73,25,64,971.85 | 6,19,215 |
13-May-2025 | 628 | 638.4 | 625.95 | 629.45 | 30,283 | 69,84,84,657.2 | 6,06,631 |
14-May-2025 | 629.45 | 642 | 627.35 | 640.85 | 30,973 | 63,02,06,196.1 | 5,04,763 |
15-May-2025 | 641 | 642.45 | 635.3 | 638.35 | 13,441 | 26,24,18,801.8 | 1,72,957 |
16-May-2025 | 639.1 | 649.7 | 633.3 | 645.4 | 30,436 | 92,21,00,923.4 | 8,54,454 |
19-May-2025 | 645.4 | 649 | 641 | 642 | 14,206 | 27,92,20,761.65 | 2,25,982 |
20-May-2025 | 645 | 645 | 627.3 | 628.5 | 17,741 | 31,38,75,424.95 | 2,58,541 |
21-May-2025 | 632.4 | 642.85 | 630.4 | 639.35 | 26,801 | 37,85,08,868.9 | 2,25,084 |
22-May-2025 | 639.25 | 640.5 | 632.25 | 635.1 | 12,912 | 19,74,62,414 | 1,72,573 |
23-May-2025 | 635.15 | 639.9 | 631.55 | 637.25 | 17,521 | 42,48,09,562.3 | 4,66,164 |
26-May-2025 | 637.3 | 652 | 636.5 | 650.15 | 20,883 | 45,26,82,003.75 | 3,62,631 |
27-May-2025 | 653.5 | 657.3 | 648.15 | 654.15 | 21,581 | 1,91,28,83,789.1 | 24,26,871 |
28-May-2025 | 655 | 655 | 647 | 650.25 | 19,238 | 77,83,72,816 | 8,26,661 |
29-May-2025 | 650.05 | 652.45 | 643.55 | 647.75 | 15,428 | 33,13,95,741.95 | 3,29,958 |
30-May-2025 | 650 | 651.9 | 642.8 | 646.55 | 11,482 | 16,40,45,997.7 | 1,44,365 |
02-Jun-2025 | 642.05 | 651.45 | 642 | 649 | 20,840 | 37,34,90,604.75 | 3,55,432 |
03-Jun-2025 | 650.25 | 654.4 | 638.5 | 641.05 | 13,808 | 22,94,07,452.55 | 1,68,025 |
04-Jun-2025 | 641.05 | 648.65 | 639.9 | 647.4 | 10,544 | 15,24,97,116.55 | 1,32,117 |
05-Jun-2025 | 651 | 651.95 | 645.85 | 646.7 | 8,823 | 14,29,11,035.75 | 1,20,483 |
06-Jun-2025 | 646.7 | 649.55 | 641.95 | 646.05 | 10,622 | 16,85,62,749.95 | 1,35,042 |
09-Jun-2025 | 646.05 | 659 | 646.05 | 656.45 | 15,154 | 52,49,81,534.75 | 4,91,402 |
The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.
The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.
This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.
The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
